Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

PVD in diabetes

Discussion in 'Diabetic Foot & Wound Management' started by NewsBot, Apr 22, 2006.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    An Evaluation of the Efficacy of Methods Used in Screening for Lower-Limb Arterial Disease in Diabetes.
    Perspect Vasc Surg Endovasc Ther. 2006 Mar;18(1):81
     
  2. Admin2

    Admin2 Administrator Staff Member

  3. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The influence of diabetes and lower limb arterial disease on cutaneous foot perfusion.
    J Vasc Surg. 2006 Aug 22;
    Williams DT, Price P, Harding KG
     
  4. markjohconley

    markjohconley Well-Known Member

    any one know ........ are tbi's potentially as invasive as abi's in dislodging emboli from thrombi (re. use of cuffs) ie can digital arteries be atherosclerotic? and do the sound waves of doppler u/s have invasive properties, again dislodging emboli (also relevant to performing lower leg arterial waveform analyses)? ... thanks, mark c
     
  5. Asher

    Asher Well-Known Member

    Hi Mark

    I've been reading the archives. I'm interested in the answer to your question also.

    It seems the ABI is the test that podiatrists can do in detecting the degree of peripheral arterial disease (PAD). How much of a risk is the use of the cuff to embolism? I have read quite a bit on the subject of ABI recently and I have not come across any mention of it.

    Rebecca
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Impact of peripheral arterial disease in patients with diabetes-Results from PROactive (PROactive 11).
    Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; on behalf of the PROactive investigators.
    Atherosclerosis. 2008 Mar 18. [Epub ahead of print]
     
  7. Mart

    Mart Well-Known Member


    My understanding of the potentialy harmful tissue effects of US are that it is less to do with the vibrational effects of the sound waves but more the effects of cavitation (creation of gas bubbles created within body fluids). Diagnostic US equipement is designed to limit energy output below body tissue cavitation levels as opposed to therapeutic US which is designed to allow this. When you use your US cleaner for your instruments or tissue debridement it is the bubbles created by the vibrations which do the work not the sound waves themselves.

    cheers

    Martin


    The St. James Foot Clinic
    1749 Portage Ave.
    Winnipeg
    Manitoba
    R3J 0E6
    phone [204] 837 FOOT (3668)
    fax [204] 774 9918
    www.winnipegfootclinic.com
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Sub-clinical vascular disease in type 2 diabetic subjects: relationship with chronic complications of diabetes and the presence of cardiovascular disease risk factors.
    Mostaza JM, Suarez C, Manzano L, Cairols M, López-Fernández F, Aguilar I, Diz Lois F, Sampedro JL, Sánchez-Huelva H, Sanchez-Zamorano MA,
    Eur J Intern Med. 2008 Jun;19(4):255-60
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Prevalence of peripheral arterial disease in patients with diabetes mellitus in a primary care setting.
    Rabia K, Khoo EM.
    Med J Malaysia. 2007 Jun;62(2):130-3.
     
  10. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The association between diabetes mellitus and the prevalence of intermittent claudication: the HUNT study.
    Jensen SA, Vatten LJ, Myhre HO.
    Vasc Med. 2008 Nov;13(4):239-44.
     
  11. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, Soong CV.
    Vasc Endovascular Surg. 2009 Apr-May;43(2):132-43.
     
  12. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers.
    Altavilla D, Bitto A, Polito F, Marini H, Minutoli L, Di Stefano V, Irrera N, Cattarini G, Squadrito F.
    Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):313-21.
     
  13. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    An assessment of peripheral vascular disease in patients with diabetic foot ulcer.
    Ikem R, Ikem I, Adebayo O, Soyoye D.
    Foot (Edinb). 2010 Oct 14. [Epub ahead of print]
     
  14. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
    de Franciscis S, Gallelli L, Battaglia L, Molinari V, Montemurro R, Stillitano DM, Buffone G, Serra R.
    Int Wound J. 2013 May 15.
     
  15. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Association of diabetic foot ulcers with chronic vascular diabetic complications in patients with type 2 diabetes
    Magdy H.MegallaaAzza A.IsmailMohammed H.ZeitounMai S.Khalifa
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews 24 January 2019
     
  16. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease
    Bayram Colak, Atilla Orhan, Ilhan Ece, Serdar Yormaz, Huseyin Yilmaz, Mustafa Sahin
    Ann Ital Chir. 2020;91:225-232.
     
  17. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Accuracy of the defining characteristics of the nursing diagnosis ineffective peripheral tissue perfusion in patients with diabetic foot
    Paula Vitória Costa Gontijo et al
    Int J Nurs Knowl. 2023 Jan 17
     
  18. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review
    Vivienne Chuter et al
    Diabetes Metab Res Rev. 2023 Jul 21
     
  19. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Challenging the angiosome concept: Delineating peripheral arterial disease patterns in diabetic foot ulcers
    Elham Sahebalzamani et al
    Vascular. 2024 May 10:17085381241254430
     
  20. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Clinical evaluation of vasculopathy in
    diabetic foot and its impact on surgical
    outcome

    Raghuveer M N et al
    Source
     
  21. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Effects of Cilostazol and Aspirin on Diabetic Foot Ulcer and Peripheral Artery Disease: A Retrospective Study
    J A Jayalal et al
    Cureus. 2025 Mar 20;17(3):e80929 https://pubmed.ncbi.nlm.nih.gov/40255702/
    Diabetic foot ulcer (DFU) remains a serious complication of diabetes, with a significant prevalence of peripheral artery disease (PAD) in affected patients. PAD complicates DFU healing, reducing recovery rates significantly. In other settings, cilostazol, a phosphodiesterase-3 inhibitor, has shown promise in reducing the risk of arterial thrombosis more effectively than aspirin, despite the traditional recommendation of aspirin to mitigate the heightened cardiovascular risk associated with diabetes. This study retrospectively compared the effects of cilostazol and aspirin on wound healing and PAD symptoms in patients with DFU. We evaluated 60 patients with DFU and PAD treated with either cilostazol or aspirin retrospectively for wound healing progression, clinical improvement, and alleviation of PAD symptoms. As 10 patients' data were incomplete, it included 50 patients from two cohorts. There were 30 patients in the cilostazol cohort and 20 in the aspirin cohort. We assessed the wound using Wagner's classification and planimetric techniques and classified the PAD stages using the Fontaine classification. Results indicated that cilostazol treatment led to a significantly higher rate of complete wound healing (90%) compared to aspirin (55%) and a faster healing timeline. Cilostazol also demonstrated a more effective improvement in PAD symptoms, facilitating a better quality of life for patients. These findings suggest that cilostazol may offer a more effective treatment option for promoting wound healing and managing PAD in DFU patients than aspirin. We recommend further randomized and controlled studies to validate these results and refine DFU treatment protocols. Protocols that incorporate cilostazol could lead to significant advancements in patient care, ultimately reducing the burden of diabetic foot ulcers. As healthcare providers seek more effective therapies, understanding the mechanisms behind cilostazol's efficacy will be crucial for optimizing treatment strategies.
     
Loading...

Share This Page